- Home
- BGLC vs DWTX Comparison
BGLC vs DWTX Comparison
Compare BGLC & DWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- DWTX
- Stock Information
- Founded
- BGLC 2017
- DWTX 2012
- Country
- BGLC Malaysia
- DWTX United States
- Employees
- BGLC N/A
- DWTX N/A
- Industry
- BGLC Medical Specialities
- DWTX
- Sector
- BGLC Health Care
- DWTX
- Exchange
- BGLC Nasdaq
- DWTX NYSE
- Market Cap
- BGLC 5.8M
- DWTX 5.9M
- IPO Year
- BGLC N/A
- DWTX N/A
- Fundamental
- Price
- BGLC $0.24
- DWTX $4.16
- Analyst Decision
- BGLC
- DWTX
- Analyst Count
- BGLC 0
- DWTX 0
- Target Price
- BGLC N/A
- DWTX N/A
- AVG Volume (30 Days)
- BGLC 1.4M
- DWTX 3.1M
- Earning Date
- BGLC 05-14-2025
- DWTX 03-31-2025
- Dividend Yield
- BGLC N/A
- DWTX N/A
- EPS Growth
- BGLC N/A
- DWTX N/A
- EPS
- BGLC N/A
- DWTX N/A
- Revenue
- BGLC $9,259,858.00
- DWTX N/A
- Revenue This Year
- BGLC N/A
- DWTX N/A
- Revenue Next Year
- BGLC N/A
- DWTX N/A
- P/E Ratio
- BGLC N/A
- DWTX N/A
- Revenue Growth
- BGLC N/A
- DWTX N/A
- 52 Week Low
- BGLC $0.21
- DWTX $1.62
- 52 Week High
- BGLC $1.00
- DWTX $29.28
- Technical
- Relative Strength Index (RSI)
- BGLC 40.98
- DWTX N/A
- Support Level
- BGLC $0.23
- DWTX N/A
- Resistance Level
- BGLC $0.32
- DWTX N/A
- Average True Range (ATR)
- BGLC 0.03
- DWTX 0.00
- MACD
- BGLC -0.00
- DWTX 0.00
- Stochastic Oscillator
- BGLC 41.17
- DWTX 0.00
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.
About DWTX DOGWOOD THERAPEUTICS INC
Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM) and Long-COVID (LC). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.